June 6, 2024MedScienOpen Access

Interleukin-10 (IL-10) in Cancer Immunotherapy

View Full Paper

Ask AI

Bookmark

Authors

YHYanfei HeChina Pharmaceutical University

Discussion

Member takes

Implication

Review reveals regulatory functions of interleukin-10 across preclinical models and human cancers, highlighting the therapeutic potential of cytokine-targeted interventions.

Key Points

Interleukin-10 therapies achieve notable antitumor responses in select malignancies, balancing cytokine-driven activation with suppression of inflammatory processes.
Assessment across animal models and clinical studies reveals that pegylated recombinant human IL-10 effectively reverses immune suppression in targeted cancer cohorts.
Highlights the therapeutic viability of IL-10 inhibitors in cancer immunotherapy, though complex regulatory actions across diverse malignancies require further clinical trials.

Cite This Study

Yanfei He (2024) studied this question.

synapsesocial.com/papers/68e65e26b6db6435875ec35e https://doi.org/10.61173/6a6hm842

View Full Paper

Ask AI

Bookmark

Implication

Review reveals regulatory functions of interleukin-10 across preclinical models and human cancers, highlighting the therapeutic potential of cytokine-targeted interventions.

Interleukin-10 (IL-10) in Cancer Immunotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Interleukin-10 (IL-10) in Cancer Immunotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider